Advanced search
Publication Cover
Modern Rheumatology Volume 26, 2016 - Issue 4
Journal homepage
617
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Safety and efficacy of upfront graded administration of trimethoprim–sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study

Yasuhiro SuyamaImmuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan, Correspondence[email protected]
,
Masato OkadaImmuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan,
,
Ryo RokutandaImmuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan,
,
Chisun MinImmuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan,
,
Belinda SasséImmuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan,
,
Daiki KobayashiCenter for Clinical Epidemiology, St Luke’s Life Science Institute, Tokyo, Japan,
,
Osamu TakahashiCenter for Clinical Epidemiology, St Luke’s Life Science Institute, Tokyo, Japan,
,
Gautam A. DeshpandeCenter for Clinical Epidemiology, St Luke’s Life Science Institute, Tokyo, Japan,
,
Kazuo MatsuiDepartment of Rheumatology, Kameda Medical Center, Kamogawa City, Chiba, Japan, and
,
Yasushi KawaguchiInstitute of Rheumatology, Tokyo Women’s Medical University, Shinjuku-Ku, Tokyo, Japan
&
Mitsumasa KishimotoImmuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan,
show all
Pages 557-561 | Received 04 Aug 2015, Accepted 15 Oct 2015, Published online: 17 Feb 2016

References

  • Thomas G, Mancini J, Jourde-Chiche N, Sarlon G, Amoura Z, Harle JR, et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple cause-of-death analysis. Arthritis Rheumatol. 2014;66:2503–11.
  • Bodro M, Paterson DL. Has the time come for routine trimethoprim–sulfamethoxazole prophylaxis in patients taking biologic therapies? Clin Infect Dis. 2013;56:1621–8.
  • Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1:573–82.
  • Katsuyama T, Saito K, Kubo S, Nawata M, Tanaka Y. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther. 2014;16:R43.
  • Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol. 2008;14:267–72.
  • Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358–63.
  • Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol. 1992;19:265–9.
  • Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:480–4.
  • Jeffries M, Bruner G, Glenn S, Sadanandan P, Carson CW, Harley JB, et al. Sulpha allergy in lupus patients: a clinical perspective. Lupus. 2008;17:202–5.
  • Para MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black JR. Reduced toxicity with gradual initiation of trimethoprim–sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr. 2000;24:337–43.
  • Pyle RC, Butterfield JH, Volcheck GW, Podjasek JC, Rank MA, Li JT, et al. Successful outpatient graded administration of trimethoprim–sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract. 2014;2:52–8.
  • Takenaka K, Komiya Y, Ota M, Yamazaki H, Nagasaka K. A dose-escalation regimen of trimethoprim–sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases. Mod Rheumatol. 2013;23:752–8.
  • Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum. 2011;41:497–502.
  • Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J. 2006;8:E20–6.
  • Rokutanda R, Kishimoto M, Ohde S, Shimizu H, Nomura A, Suyama Y, et al. Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis. Rheumatol Int. 2014;34:59–62.
  • Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al. Comparison of atovaquone (566C80) with trimethoprim–sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521–7.
  • Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, et al. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus. 2012;21:1444–9.
  • Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, et al. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther. 2007;9:R23.
  • Chen X, Quinn AM, Wolin SL. Ro ribonucleoproteins contribute to the resistance of Deinococcus radiodurans to ultraviolet irradiation. Genes Dev. 2000;14:777–82.
  • Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum. 2008;59:1034–9.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
  • Douglas R, Spelman D, Czarny D, O’Hehir RE. Successful desensitization of two patients who previously developed Stevens–Johnson syndrome while receiving trimethoprim–sulfamethoxazole. Clin Infect Dis. 1997;25:1480.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.